BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. SUN
PHARMACEUTICAL INDUSTRIES LTD et al. 3:16-cv-01727; Filed: 03/29/2016;
www.leagle.com/decision/1995235234Conn1_1235/TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
234 Conn. 1 (1995). ANUSHAVAN G. TOROSYAN v. BOEHRINGER INGELHEIM
PHARMACEUTICALS, INC. Supreme Court of Connecticut. Argued March 21 ...
Apr 3, 2014 ... KG, ET AL., C.A. No. 3:13-01776. Eastern District of Pennsylvania. MIAMI-LUKEN
, INC. V. BOEHRINGER INGELHEIM PHARMA GMBH & CO.
Comparisons between treatment arms (acamprosate vs placebo) were made by
the .... Tiihonen et al found similar benefit in 62 alcoholic patients. ... served in
advisory/consultative relationships with Boehringer Ingelheim and Pfizer. ... Inc,
Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc, Wyeth-Ayerst
AZA 5-2-2, p = 0.0021; AZA 5 vs. AZA 7, p ... Table 3. Assigned scores in lower-
risk patients based on the prognostic score described by Garcia-Manero et al.
... benefit of this analogue in reducing the risk of hypoglycemia (Bazzano et al.,
2008). .... period was higher with NPH, compared with glargine (15,527 vs 11,995
). ..... al., 2001; J. Rosenstock, S.L. Schwartz, C.M. Clark Jr., G.D. Park, D.W.
Donley, ... Johnson, Novartis and Boehringer Ingelheim, and Amylin
As part of the “extended amygdala” (Alheid and Heimer 1988; Alheid et al. ....
ANOVA indicated a significant effect of Stress Level (i.e., before vs. after shock), F
(1 .... meloxicam (Metacam, Boehringer Ingelheim) to reduce post-operative
discomfort. ... was facilitated with 0.5 mg/kg atipamezole HCl (Antisedan, Orion
et al. 2009), intra-BNST infusions of calcitonin gene-related pep- tide (CGRP) ...
2004; Donley et al. .... significant effect of Stress Level (i.e., before vs. after shock)
,. F(1,14) ..... dexmedetomidine HCl (Dexdomitor, Orion Pharma), and received ...
Boehringer Ingelheim) to reduce post-operative discomfort. .... Glassbeads Inc.).